[11], a 30-year-old man with a new deep vein thrombosis (DVT) in the context of heterozygous prothrombin gene mutation who was receiving valproic acid (1000 mg daily) was switched to dabigatran (150 mg twice daily) one month after the diagnosis of DVT after a lack of clinical improvement and low levels on rivaroxaban. This evidence concerns the gene F2 and deep vein thrombosis.